AstraZeneca PLC ADR Stock Forecast:
Based on the forecast and analysis from 9 analysts, the average target price for AstraZeneca PLC ADR stock over the next 12 months is USD 87.60. The average analyst rating is Strong Buy, indicating positive sentiment towards the stock. However, Stock Target Advisor’s own analysis rates the stock as Neutral, considering 8 positive signals and 7 negative signals.
As of the last closing, AstraZeneca PLC ADR’s stock price was USD 74.25. Over the past week, the stock price has increased by +1.94%, but it has decreased by -1.43% over the past month. However, the stock has shown significant growth of +14.72% over the last year.
Latest Target Changes:
Barclays reiterates their Overweight rating for AstraZeneca
J.P. Morgan reiterates their Overweight rating for AstraZeneca (AZN:NSD)
AstraZeneca PLC News:
In a significant development for pediatric healthcare, the U.S. Food and Drug Administration (FDA) advisers have given their unanimous support for the use of an experimental antibody, nirsevimab, developed by Sanofi SA in collaboration with AstraZeneca Plc. The antibody aims to prevent respiratory syncytial virus (RSV) infections in infants. The advisory panel endorsed the use of nirsevimab in newborns and infants to protect them during their first RSV season. Additionally, they voted overwhelmingly in favor of extending the therapy’s use for vulnerable children aged up to two years, who may face severe illness in their second RSV season.
The experimental antibody, nirsevimab, is designed to provide passive immunity by targeting RSV. It works by binding to the RSV fusion (F) protein, preventing it from entering human cells and causing infection. The antibody has shown promising results in clinical trials, demonstrating its ability to reduce RSV-associated lower respiratory tract infections and hospitalizations in infants. With the FDA advisers’ endorsement, nirsevimab has taken a step closer to becoming a much-needed preventive tool in the fight against RSV infections.
